Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PEN Stock Forecast 2025-2026
$266.19
Current Price
$10.42B
Market Cap
Buy 16
Hold 3
Sell 1
Wall St Analyst Ratings
Distance to PEN Price Targets
+33.4%
To High Target of $355.00
+20.2%
To Median Target of $320.00
-30.1%
To Low Target of $186.00
PEN Price Momentum
+17.1%
1 Week Change
+1.8%
1 Month Change
+12.6%
1 Year Change
+12.1%
Year-to-Date Change
-14.1%
From 52W High of $310.00
+20.3%
From 52W Low of $221.26
📊 TOP ANALYST CALLS
Did PEN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Penumbra is one of their latest high-conviction picks.
Latest PEN Stock Price Targets & Analyst Predictions
Based on our analysis of 22 Wall Street analysts, PEN has a bullish consensus with a median price target of $320.00 (ranging from $186.00 to $355.00). The overall analyst rating is Strong Buy (8.8/10). Currently trading at $266.19, the median forecast implies a 20.2% upside. This outlook is supported by 16 Buy, 3 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Jason Mills at Canaccord Genuity, projecting a 33.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PEN Analyst Ratings
16
Buy
3
Hold
1
Sell
PEN Price Target Range
Low
$186.00
Average
$320.00
High
$355.00
Current: $266.19
Latest PEN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PEN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 6, 2025 | JP Morgan | Robert Marcus | Neutral | Maintains | $275.00 |
| Nov 6, 2025 | Canaccord Genuity | Jason Mills | Buy | Maintains | $355.00 |
| Oct 27, 2025 | Needham | Mike Matson | Buy | Reiterates | $326.00 |
| Oct 27, 2025 | BTIG | Ryan Zimmerman | Buy | Reiterates | $320.00 |
| Oct 15, 2025 | Truist Securities | Richard Newitter | Buy | Maintains | $300.00 |
| Oct 8, 2025 | Needham | Mike Matson | Buy | Upgrade | $326.00 |
| Oct 7, 2025 | Evercore ISI Group | Vijay Kumar | Outperform | Maintains | $285.00 |
| Sep 2, 2025 | Evercore ISI Group | Vijay Kumar | Outperform | Initiates | $300.00 |
| Jul 31, 2025 | Morgan Stanley | Kallum Titchmarsh | Equal-Weight | Maintains | $266.00 |
| Jul 30, 2025 | RBC Capital | Shagun Singh | Outperform | Maintains | $325.00 |
| Jul 30, 2025 | Baird | David Rescott | Outperform | Maintains | $285.00 |
| Jul 30, 2025 | Wells Fargo | Larry Biegelsen | Overweight | Maintains | $290.00 |
| Jul 30, 2025 | Canaccord Genuity | Jason Mills | Buy | Maintains | $350.00 |
| Jul 30, 2025 | UBS | Priya Sachdeva | Buy | Maintains | $335.00 |
| Jul 30, 2025 | Truist Securities | David Rescott | Buy | Maintains | $310.00 |
| Jul 9, 2025 | Citigroup | Joanne Wuensch | Neutral | Maintains | $285.00 |
| Apr 24, 2025 | UBS | Priya Sachdeva | Buy | Maintains | $330.00 |
| Apr 24, 2025 | Wells Fargo | Larry Biegelsen | Overweight | Maintains | $315.00 |
| Apr 24, 2025 | Truist Securities | David Rescott | Buy | Maintains | $330.00 |
| Apr 24, 2025 | Baird | David Rescott | Outperform | Maintains | $325.00 |
Penumbra Inc. (PEN) Competitors
The following stocks are similar to Penumbra based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Penumbra Inc. (PEN) Financial Data
Penumbra Inc. has a market capitalization of $10.42B with a P/E ratio of 63.7x. The company generates $1.33B in trailing twelve-month revenue with a 12.3% profit margin.
Revenue growth is +17.8% quarter-over-quarter, while maintaining an operating margin of +13.8% and return on equity of +13.3%.
Valuation Metrics
Market Cap
$10.42B
Enterprise Value
$10.17B
P/E Ratio
63.7x
PEG Ratio
-0.4x
Price/Sales
7.8x
Growth & Margins
Revenue Growth (YoY)
+17.8%
Gross Margin
+66.0%
Operating Margin
+13.8%
Net Margin
+12.3%
EPS Growth
+55.3%
Financial Health
Cash/Price Ratio
+4.5%
Current Ratio
6.7x
Debt/Equity
16.0x
ROE
+13.3%
ROA
+6.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Penumbra Inc. (PEN) Business Model
About Penumbra Inc.
What They Do
Develops innovative medical devices for healthcare.
Business Model
Penumbra Inc. generates revenue through the development and commercialization of advanced medical devices, specifically targeting interventional therapies in neuro and vascular fields. The company focuses on creating minimally invasive solutions that help treat critical conditions, thereby establishing partnerships with healthcare providers and hospitals to enhance patient care and optimize treatment outcomes.
Additional Information
Founded in 2004 and headquartered in Alameda, California, Penumbra plays a significant role in the medical device industry. Its commitment to innovation and improving healthcare technologies positions it as a key player in the market, with a strong emphasis on customer-centric solutions that meet the needs of patients and healthcare professionals.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
4,500
CEO
Mr. Adam Elsesser J.D.
Country
United States
IPO Year
2015
Website
www.penumbrainc.comPenumbra Inc. (PEN) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Penumbra (PEN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Penumbra (PEN) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Nov 05, 2025
By Zacks Equity Research
Fundamental Analysis
Penumbra (PEN) Q3 Earnings and Revenues Beat Estimates
Penumbra (PEN) delivered earnings and revenue surprises of +7.78% and +4.12%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Nov 05, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Penumbra's stock surged after the company exceeded third-quarter earnings expectations, driven by strong performance in its blood-clot-removing technology.
Why It Matters
Penumbra's stock surge reflects strong performance and investor confidence in its innovative technology, potentially signaling future growth and profitability.
Source: Investors Business Daily
Market Sentiment:
Positive
Quick Summary
Penumbra, Inc. (PEN) will hold its Q3 2025 earnings call on November 5, 2025, at 4:30 PM EST with company executives and analysts from various financial institutions participating.
Why It Matters
The earnings call for Penumbra, Inc. indicates upcoming insights on financial performance and strategic direction, impacting stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Penumbra, Inc. (NYSE: PEN) announced its third-quarter financial results for the period ending September 30, 2025. Further details on performance were not included.
Why It Matters
Penumbra's Q3 financial results can influence stock performance, indicating company growth or challenges, impacting investor confidence and decision-making.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Penumbra (PEN) reported Q3 earnings of $0.97 per share, exceeding the Zacks Consensus Estimate of $0.90, and up from $0.85 per share in the same quarter last year.
Why It Matters
Penumbra's earnings beat estimates and show growth year-over-year, indicating strong performance and potential for future profitability, which can positively influence investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Penumbra (PEN) reported its revenue and EPS for Q3 2025, with key metrics suggesting comparison to Wall Street estimates and year-ago figures may be important for investors.
Why It Matters
Comparing Penumbra's revenue and EPS with Wall Street estimates and prior year figures provides insight into growth trends and market expectations, impacting investor sentiment and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Penumbra, Inc. (NYSE: PEN) reported at the VIVA 2025 Conference that its STORM-PE trial showed CAVT combined with anticoagulation significantly improved outcomes for pulmonary embolism patients versus anticoagulation alone.
Why It Matters
Penumbra's STORM-PE trial shows CAVT combined with anticoagulation significantly improves outcomes for PE patients, potentially boosting demand for their technology and impacting stock performance positively.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About PEN Stock
What is Penumbra Inc.'s (PEN) stock forecast for 2026?
Based on our analysis of 22 Wall Street analysts, Penumbra Inc. (PEN) has a median price target of $320.00. The highest price target is $355.00 and the lowest is $186.00.
Is PEN stock a good investment in 2026?
According to current analyst ratings, PEN has 16 Buy ratings, 3 Hold ratings, and 1 Sell ratings. The stock is currently trading at $266.19. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PEN stock?
Wall Street analysts predict PEN stock could reach $320.00 in the next 12 months. This represents a 20.2% increase from the current price of $266.19. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Penumbra Inc.'s business model?
Penumbra Inc. generates revenue through the development and commercialization of advanced medical devices, specifically targeting interventional therapies in neuro and vascular fields. The company focuses on creating minimally invasive solutions that help treat critical conditions, thereby establishing partnerships with healthcare providers and hospitals to enhance patient care and optimize treatment outcomes.
What is the highest forecasted price for PEN Penumbra Inc.?
The highest price target for PEN is $355.00 from Jason Mills at Canaccord Genuity, which represents a 33.4% increase from the current price of $266.19.
What is the lowest forecasted price for PEN Penumbra Inc.?
The lowest price target for PEN is $186.00 from at , which represents a -30.1% decrease from the current price of $266.19.
What is the overall PEN consensus from analysts for Penumbra Inc.?
The overall analyst consensus for PEN is bullish. Out of 22 Wall Street analysts, 16 rate it as Buy, 3 as Hold, and 1 as Sell, with a median price target of $320.00.
How accurate are PEN stock price projections?
Stock price projections, including those for Penumbra Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: November 9, 2025 6:37 AM UTC